Tianjin Chase Sun Pharmaceutical saw no growth in patent filings and highest growth of 1.49% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.49%. GlobalData’s DataBook provides a comprehensive analysis of Tianjin Chase Sun Pharmaceutical’s patent filings and grants. Buy the databook here.
Tianjin Chase Sun Pharmaceutical has been focused on protecting inventions in China(CN) with three publications in Q2 2024
The China(CN) Patent Office dominates the patent filings and grants with nearly 100% filings and 67% grants. The China(CN), European Patent Office(EPO), and United States(US) patent Office are among the top ten patent offices where Tianjin Chase Sun Pharmaceutical is filings its patents. Among the top granted patent authorities, Tianjin Chase Sun Pharmaceutical has 67% of its grants in China(CN) and 33% in United States(US).
Roche could be the strongest competitor for Tianjin Chase Sun Pharmaceutical
Sepsis related patents lead Tianjin Chase Sun Pharmaceutical portfolio
Tianjin Chase Sun Pharmaceutical has highest number of patents in sepsis.
For comprehensive analysis of Tianjin Chase Sun Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.